DOI: 10.12890/2025_005869
Pseudohypoaldosteronism type II: the relevance of a challenging diagnosis
Authors
daniela.lr.cruz@gmail.com
Keywords
Pseudohypoaldosteronism type II, Gordon syndrome, hyperkalaemia, low renin hypertension, KLHL3 geneAbstract
Pseudohypoaldosteronism type II (PHA II) is a rare genetic syndrome caused by mutations in the WNK1, WNK4, KLHL3 and CUL3 genes, leading to hypertension, hyperkalaemia, and hyperchloremic metabolic acidosis. Each mutation confers a different phenotype, with a large spectrum of clinical presentations, which can delay the diagnosis. We report a case of a 31-year-old female with hypertension. She had uncharacteristic facies, average height and no family history of hypertension or hyperkalaemia. Laboratory data showed hyperkalaemia, hyperchloremic metabolic acidosis, hypercalciuria and suppressed renin. Genetic testing revealed a c.478G>T, p.(Asp160Tyr) variant in the KLHL3 gene, in apparent homozygosity. Based on clinical history, laboratory findings, and genetic testing, a diagnosis of PHA II was made. This is a representative case of a mild PHA II phenotype, with a non-previously reported KLHL3 mutation, highlighting the importance of a high level of suspicion for PHA II.
References
- Riepe FG. Pseudohypoaldosteronism. Endocr Dev 2013;24:86-95. doi: 10.1159/000342508
- Mabillard H, Sayer JA. The molecular genetics of Gordon syndrome. Genes (Basel) 2019;10:986. doi: 10.3390/genes10120986
- O’Shaughnessy KM. Gordon syndrome: a continuing story. Pediatr Nephrol 2015;30:1903-1908. doi: 10.1007/s00467-014-2956-7
- Ellison DH. Pseudohypoaldosteronism type II. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023 [updated 2017 Feb 16; cited 2025 Sep 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6575/ PMID: 22073419.
- Etges A, Hellmig N, Walenda G, Haddad BG, Machtens JP, Morosan T, et al. A novel homozygous KLHL3 mutation as a cause of autosomal recessive pseudohypoaldosteronism type II diagnosed late in life. Nephron 2022;146:418-428. doi: 10.1159/000521626
- Park JS, Park E, Hyun HS, Ahn YH, Kang HG, Ha IS, et al. Three cases of Gordon syndrome with dominant KLHL3 mutations. J Pediatr Endocrinol Metab 2017;30:361-364. doi: 10.1515/jpem-2016-0309
- Zhang R, Zhang S, Luo Y, Li M, Wen X, Cai X, et al. A case report of pseudohypoaldosteronism type II with a homozygous KLHL3 variant accompanied by hyperthyroidism. BMC Endocr Disord 2021;21:103. doi: 10.1186/s12902-021-00767-w
- Toka HR, Dhir R, Toka O, Hariri A, Schieffer B, Williams GH, et al. The molecular basis of blood pressure variation. Pediatr Nephrol 2013;28:387-399. doi: 10.1007/s00467-012-2206-9
- Athimulam S, Lazik N, Bancos I. Low-renin hypertension. Endocrinol Metab Clin North Am 2019;48:701-715. doi: 10.1016/j.ecl.2019.08.003
- Glover M, Zuber AM, O’Shaughnessy KM. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. Cardiovasc Ther 2011;29:68-76. doi: 10.1111/j.1755-5922.2010.00180.x
